Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Healthy volunteers for Neuroinflammatory research study

Healthy volunteers for Neuroinflammatory research study

18 years - 60 years
Accepts healthy volunteer
All genders
We are conducting research studies on how immune system cells contribute to inflammatory conditions of the nervous system, such as multiple sclerosis, neuromyelitis optica (NMO), encephalitis, head injury, epilepsy, Parkinson's disease (PD), Alzheimer's disease (AzD), Lou Gherig's disease (amyotrophic lateral sclerosis; ALS) frontotemporal dementia (FTD) and others. This includes investigating …
Learn More

UPCC 17418: A Phase 2b Open-Label Single Arm Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Standard Induction Therapy

99 years or below
All genders
Phase 2
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
Learn More

UPCC 17419: A Phase 1b-2 Open-Label Study of JNJ-68284528 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

99 years or below
All genders
Phase 2
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
Learn More

Evaluation of Hyperfine Low Field Portable Point-of-Care Magnetic Resonance Imaging System in Patients with Hydrocephalus

99 years or below
All genders
Hydrocephalus is a medical condition in which an abnormal buildup of cerebrospinal fluid (CSF) causes the fluid-filled spaces of the brain, the ventricles, to become enlarged. Enlarged ventricles and increased intracranial pressure can cause headaches, dizziness, blurred vision, cognitive impairment, gait disturbances and in severe cases even brain herniation or …
Learn More

UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

99 years or below
All genders
Phase 2
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
Learn More

UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma

99 years or below
All genders
Phase 1
Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …
Learn More

UPCC 13418: A Multicenter Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

99 years or below
All genders
Phase 1
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
Learn More

UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab

99 years or below
All genders
Phase 2
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
Learn More

Observational Study of Outcomes after EchoMark and EchoSure-based Free Flap Monitoring

99 years or below
All genders
The purpose of this study is to evaluate the performance of the EchoMark and EchoSure (both FDA approved devices) as an ultrasound-based method of monitoring the viability of free flaps and patency of at-risk vessels. The implant and ultrasound will be used per IFU. The primary purpose of the study …
Learn More

Implementing the screen and treat strategy for prevention of cryptococcal disease in Botswana: An efficacy and costing study (study protocol V1.5 16th March 2017)

99 years or below
All genders
Adult HIV prevalence in Botswana is estimated at 25%. In 2013, despite widespread availability of antiretroviral therapy (ART), an estimated one-quarter of patients did not initiate ART until their CD4 count was below 147 cells/microL. The early mortality rate in these individuals is high, and cryptococcal meningitis is a leading …
Learn More
881 - 890 of 1243